CzernobilskyB.Primary epithelial tumors of the ovary In: BlausteinA., ed. Pathology of the Female Genital Tract.2nd ed.New York, NY: Springer-Verlag; 1982: 511–560.
6.
RussellP.The pathological assessment of ovarian neoplasms: II. The proliferating “epithelial” tumours. Pathology.1979; 11: 251–282.
7.
HarlowB.L., WeissN.S., RothG.J.Case-control study of borderline ovarian tumors: reproductive history and exposure to exogenous hormones. Cancer Res.1988; 48: 5849–5852.
8.
KurmanR.J., TrimbleC.L.The behavior of serous tumors of low malignant potential: are they ever malignant?Int J Gynecol Pathol.1993; 12: 120–127.
9.
MittalK.R., Zeleniuch-JacquotteA., CooperJ.L.Contralateral ovary in unilateral ovarian carcinoma: a search for preneoplastic lesions. Int J Gynecol Pathol.1993; 12: 59–63.
10.
FoxH.Pathology of early malignant change in the ovary. Int J Gynecol Pathol.1993; 12: 153–155.
11.
McCaugheyW.T., KirkM.E., LesterW.Peritoneal epithelial lesions associated with proliferative serous tumors of ovary. Histopathology.1984; 8: 195–208.
12.
NicosiaS.V., SaundersB.O., Acevedo-DuncanM.E.Pathobiology of ovarian mesothelium. In: FamiliariG., MakabeS., MottaP.M., eds. Ultrastructure of the Ovary.Boston, Mass: Kluwer Academic Publishers; 1991: 287–310.
13.
NicosiaS.V., NicosiaR.F., SaundersB.Control of papillogenesis in normal and neoplastic ovarian mesothelium. Front Endocrinol.1995; 13: 332–343.
14.
PierroE., NicosiaS.V., SaundersB.Influence of growth factors on proliferation and morphogenesis of ovarian mesothelial cells in vitro. Biol Reprod.1996; 54: 660–669.
15.
ColganT.J., NorrisH.J.Ovarian epithelial tumors of low malignant potential. Int J Gynecol Pathol.1983; 1: 367–382.
16.
TavassoliF.A.Serous tumors of low malignant potential with early stromal invasion (serous LMP with microinvasion). Mod Pathol.1988; 1: 407–414.
17.
HanselaarA.G., VooijsG.P., MayallB.Epithelial markers to detect occult microinvasion in serous ovarian tumors. Int J Gynecol Pathol.1993; 12: 20–27.
18.
AureJ.C., HoegK., KolstadP.Clinical and histologic studies of ovarian carcinoma: long- term follow-up of 990 cases. Obstet Gynecol.1971; 37: 1–9.
19.
BaakJ.P., Wisse-BrekelmansE.C., UyterlindeA.M.Evaluation of the prognostic value of morphometric features and cellular DNA content in FIGO I ovarian cancer patients. Anal Quant Cytol Histol.1987; 9: 287–290.
20.
FriedlanderM.L., RussellP., TaylorI.W.Flow cytometric analysis of cellular DNA content as an adjunct to the diagnosis of ovarian tumours of borderline malignancy. Pathology.1984; 16: 301–306.
21.
GriffithsA.P., CrossD., KingstonR.E.Flow cytometry and AgNORs in benign, borderline, and malignant mucinous and serous tumours of the ovary. Int J Gynecol Pathol.1993; 12: 307–314.
22.
KallioniemiO.P., PunnonenR., MattilaJ.Prognostic significance of DNA Index, multiploidy, and S-phase fraction in ovarian cancer. Cancer.1988; 61: 334–339.
23.
KotyloP.K., MichaelH., FinebergN.Flow cytometric analysis of DNA content and ras p21 oncoprotein expression in ovarian neoplasms. Int J Gynecol Pathol.1992; 11: 30–37.
24.
KlemiP.J., TakahashiS., JoensuuH.Immunohistochemical detection of p53 protein in borderline and malignant serous ovarian tumors. Int J Gynecol Pathol.1994; 13: 228–233.
25.
KhattechA., SpatzA., PradeM.Nucleolar organizer regions in ovarian tumors: discrimination between carcinoma and borderline tumor. Int J Gynecol Pathol.1992; 11: 11–14.
26.
CriscuoloM., MartinelliA.M., MigaldiM.Prognostic significance of nucleolar organizer regions in ovarian epithelial tumors. Int J Gynecol Pathol.1993; 12: 259–263.
27.
MountfordC.E., SaundersJ.K., MayG.L.Classification of human tumours by high- resolution magnetic resonance spectroscopy. Lancet.1986; 1: 651–653.
28.
HartW.R., NorrisH.J.Borderline and malignant mucinous tumors of the ovary: histologic criteria and clinical behaviour. Cancer.1973; 31: 1031–1045.
29.
ChaitinB.A., GershensonD.M., EvansH.L.Mucinous tumors of the ovary: a clinicopathological study of 70 cases. Cancer.1985; 55: 1958–1962.
30.
KahnM.A., DemopoulosR.I.Mucinous ovarian tumors with pseudomyxoma peritonei: a clinicopathological study. Int J Gynecol Pathol.1992; 11: 15–23.
31.
ZinsserK.R., WheelerJ.E.Endosalpingiosis in the omentum: a study of autopsy and surgical material. Am J Surg Pathol.1982; 6: 109–117.
32.
RussellP., BannatyneP.M llerianosis and surface proliferative lesions. In: RussellP., BannatyneP., eds. Surgical Pathology of the Ovaries.Edinburgh, Scotland: Churchill Livingstone; 1989: 157–187.
33.
FroboeseC.Peritonitis arenosa und epiploitis fibroplastica calcificans (ossificans). Virchows Arch A Pathol Anat Histopathol.1950; 317: 616–653.
34.
BellD.A., WeinstockM.A., ScullyR.E.Peritoneal implants of ovarian serous borderline tumors: histologic features and prognosis. Cancer.1988; 62: 2212–2222.
35.
ClementP.B., YoungR.H.Florid mesothelial hyperplasia associated with ovarian tumors: a potential source of error in tumor diagnosis and staging. Int J Gynecol Pathol.1993; 12: 51–58.
36.
NicosiaS.V., Erkamn-BalisB., LaPollaJ.An immunocytochemical study of reactive mesothelia, benign glandular inclusions and ovarian carcinomas in “second look” peritoneal washings. Lab Invest.1988; 58: 67a.
37.
BellD.A., ScullyR.E.Serous borderline tumors of the peritoneum. Am J Surg Pathol.1990; 14: 230–239.
38.
BurmeisterR.E., FechnerR.E., FranklinR.R.Endosalpingiosis of the peritoneum. Obstet Gynecol.1969; 34: 310–318.
39.
PickartzH.Differential diagnosis of peritoneal lesions of mullerian type and similar epithelial tumors of the peritoneum. Int J Gynecol Pathol.1993; 12: 116–119.
40.
PradeM., SpatzA., BentleyR.Borderline and malignant serous tumor arising in pelvic lymph nodes: evidence of origin in benign glandular inclusions. Int J Gynecol Pathol.1995; 14: 87–91.
41.
Dallenbach-HellwegG.Atypical endosalpingiosis: a case report with consideration of the differential diagnosis of glandular subperitoneal inclusions. Pathol Res Pract.1987; 182: 180–182.
42.
WoodruffJ.D.The pathogenesis of ovarian neoplasia. Johns Hopkins Med J.1979; 144: 117–120.
43.
HeinonenP.K., MorskyP., AineR.Hormonal activity of epithelial ovarian tumours in post-menopausal women. Maturitas.1988; 9: 325–338.
44.
KlemiP.J., JoensuuH., KiilholmaP.Clinical significance of abnormal nuclear DNA content in serous ovarian tumours. Cancer.1988; 62: 2005–2010.
45.
IversenO.E., SkaarlandE.Ploidy assessment of benign and malignant ovarian tumours by flow cytometry: a clinicopathologic study. Cancer.1987; 60: 82–87.
46.
KuhnW., KaufmannM., FeichterG.E.DNA flow cytometry, clinical and morphological parameters as prognostic factors for advanced malignant and borderline ovarian tumors. Gynecol Oncol.1989; 33: 360–367.
47.
WatsonJ.V., CurlingO.M., MunnC.F.Oncogene expression in ovarian cancer: a pilot study of c-myc oncoprotein in serous papillary ovarian cancer. Gynecol Oncol.1987; 28: 137–150.
48.
MarcelliA.R., DemopoulosR.I., GoswanniS.Comparison of p53 and MIB1 expression in benign and borderline areas of ovarian serous tumors. Int J Gynecol Pathol.1996; 15: 39–44.
49.
StrombergK., JohnsonG.R., O'ConnorD.M.Frequent immunohistochemical detection of EGF supergene family members in ovarian carcinogenesis. Int J Gynecol Pathol.1994; 13: 342–347.
50.
CalugiA., EleuteriP., CavalloD.Detection of cellular heterogeneity by DNA ploidy, 17 chromosome, and p53 gene in primary carcinoma and metastasis in a case of ovarian cancer. Int J Gynecol Pathol.1996; 15: 77–81.
